The Latest in AML

FDA’s Project Optimus aims to transform early cancer research

November 14, 2023

EHA webinar addresses treating AML patients with COVID-19

April 28, 2020

9/11 responders show increased risk of leukemia, other cancers

January 14, 2020

Genomic profiling of AML and MDS yields prognostic clues

January 9, 2020

Kidney function in African American AML patients not linked to reduced survival compared with whites

December 7, 2019

Will TP53-mutated AML respond to immunotherapy?

November 18, 2019

Hematopoietic cell transplant offers realistic cure in secondary AML

October 23, 2019

Adverse cytogenetics trump molecular risk in NPM1-mutated AML

October 15, 2019

Genetic analysis highlights value of germline variants in MDS, AML

September 18, 2019

Nonmyeloablative conditioning carries lowers infection risk in patients with AML

September 10, 2019

ADMIRAL results solidify gilteritinib as new standard for FLT3-mutated AML

June 27, 2019

Guadecitabine offers limited advantage over other standards for high-risk AML

June 26, 2019

Risk model could help predict VTE in acute leukemia

June 26, 2019

AML variants before transplant signal need for aggressive therapy

June 25, 2019

For tough AML, half respond to selinexor plus chemotherapy

June 25, 2019